Patents Examined by Gabriele Bugaisky
-
Patent number: 7176288Abstract: The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as nucleic acid constructs encoding such variants, vectors and host cells comprising and expressing the nucleic acid, pharmaceutical compositions, uses and methods of treatment.Type: GrantFiled: September 13, 2001Date of Patent: February 13, 2007Assignee: Novo Nordisk HealthCare A/GInventors: Egon Persson, Ole Hvilsted Olsen
-
Patent number: 7172901Abstract: This invention relates to an isolated nucleic acid fragment encoding scorpion toxins that are K-channel agonists. The invention also relates to the construction of a chimeric gene encoding all or a portion of the K-channel agonists, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the K-channel agonists in a transformed host cell.Type: GrantFiled: July 8, 2003Date of Patent: February 6, 2007Assignee: E. I. du Pont de Nemours and CompanyInventors: Rafael Herrmann, Jian-Ming Lee, Albert L. Lu, James K. Presnail, James F H Wong
-
Patent number: 7160986Abstract: The present invention relates to BCL-x?, a novel isoform of the BCL-x family of proteins which is predominantly expressed in T-lymphocytes and is associated with resistance to apoptosis. Both compositions of matter and methods are described which are useful in the treatment or prevention of immune system disorders.Type: GrantFiled: July 29, 2002Date of Patent: January 9, 2007Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Xiao-Feng Yang, Georg F. Weber, Harvey Cantor
-
Patent number: 7132259Abstract: The invention provides, in part, compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also provides, in part, nucleic acid molecules encoding such polypeptides, and methods of making such polypeptides and nucleic acid molecules.Type: GrantFiled: August 25, 2000Date of Patent: November 7, 2006Assignee: Allergan, Inc.Inventors: J. Oliver Dolly, Yan Li, Kuo Chion Chan
-
Patent number: 7125846Abstract: The present invention relates to a composition comprising factor VII or a factor VII-related polypeptide, and factor V or a factor V-related polypeptide, and the use thereof for treating bleeding episodes.Type: GrantFiled: November 8, 2002Date of Patent: October 24, 2006Assignee: Novo Nordisk HealthCare A/GInventor: Rasmus Rojkjaer
-
Patent number: 7125684Abstract: Two human MATER proteins as well as their use for fertility disorders, therapy and diagnosis are described.Type: GrantFiled: August 12, 2002Date of Patent: October 24, 2006Assignee: Schering AGInventors: Bertram Weiss, Monika Lessl, Michaele Peters-Kottig, Georg Beckmann
-
Patent number: 7101849Abstract: An isolated, synthetic, or recombinant ?-conotoxin peptide in which the fourth loop between cysteine residues 5 and 6 comprises SEQ ID NO: 1 or such a sequence which has undergone one or more amino acid substitutions or side chain modifications, and uses therefor. SEQ ID NO: 1 comprises the amino acid sequence SGTVGR.Type: GrantFiled: April 16, 1999Date of Patent: September 5, 2006Assignee: The University of QueenslandInventors: Roger Desmond Drinkwater, Richard James Lewis, Paul Francis Alewood, Katherine Justine Nielsen
-
Patent number: 7094586Abstract: The present invention relates to transglutaminases and transglutaminase preparations obtained from lower fungi belonging to the class Oomycetes and unprecedented high-level expression is achievable by growing these coenocytium forming organisms, especially the strains Pythium sp., Pythium irregulare, Pythium dissotocum, Pythium periilum (or P. periplocum), Pythium torulosum, Pythium ultimum, Pythium aphanidermatum, Phytophthora cactorum, Phytophthora palmivora, Phytophthora porri, Phytophthora infestans, Phytophthora megasperma, Phytophthora cinnamomi and Phytophthora cryptogea; and a recombinant transglutaminase has been cloned and expressed, the enzyme and enzyme preparations being useful for cross-linking proteins, e.g. in flour, baked products, meat products, fish products, cosmetics, cheese, milk products, gelled food products and leather finishing, or as a glutaminase, e.g. in bread and other baked glutein-containing food products.Type: GrantFiled: June 7, 2002Date of Patent: August 22, 2006Assignee: Novozymes A/SInventors: Lisbeth Bech, Grethe Rasmussen, Torben Halkier, Mariko Okada, Lene Nonboe Andersen, Markus Sakari Kauppinen, Thomas Sandal
-
Patent number: 7091312Abstract: The invention relates to novel nucleic acid and protein sequences from the mung bean Vigna radiata. The nucleic acid sequence, isolated from a bruchid resistant mung bean line, encodes a thionin-like protein with insecticidal properties.Type: GrantFiled: April 8, 2003Date of Patent: August 15, 2006Assignee: Academia SinicaInventors: Ching-San Chen, Kuan-Chung Chen, Cheng-Chun Kuan, Ching-Yu Lin
-
Patent number: 7091177Abstract: The subject invention concerns the discovery of Bacillus thuringiensis isolates with advantageous activity against weevils. In preferred embodiments of the invention, B.t. isolates, or toxins therefrom, are used to control alfalfa weevils, boll weevils, and/or rice water weevils. The toxins can be administered to the pests through a variety of methods including the transformation of bacteria or plants to produce the weevil-active toxins.Type: GrantFiled: July 30, 2003Date of Patent: August 15, 2006Assignee: Mycogen CorporationInventors: Gregory A. Bradfisch, H. Ernest Schnepf, Leo Kim
-
Patent number: 7083944Abstract: Novel CARD-12 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated CARD-12 proteins, the invention further provides CARD-12, fusion proteins, antigenic peptides and anti-CARD-12 antibodies. The invention also provides CARD-12 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a CARD-12 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: October 26, 2000Date of Patent: August 1, 2006Assignee: Millennium Pharmaceuticals, Inc.Inventors: John Bertin, Keith E. Robison
-
Patent number: 7067250Abstract: The present invention provides a DNA encoding a TADG-14 protein selected from the group consisting of: (a) isolated DNA which encodes a TADG-14 protein; (b) isolated DNA which hybridizes to isolated DNA of (a) above and which encodes a TADG-14 protein; and (c) isolated DNA differing from the isolated DNAs of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a TADG-14 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell.Type: GrantFiled: August 21, 1998Date of Patent: June 27, 2006Assignee: The University of Arkansas for Medical SciencesInventors: Lowell J. Underwood, Timothy J. O'Brien
-
Patent number: 7056888Abstract: The subject invention provides KB59A4-6 pesticidal proteins and preferred methods of using these proteins to control lepidoteran pests. This invention provides Bacillus thuringiensis isolate KB59A4-6.Type: GrantFiled: May 30, 2003Date of Patent: June 6, 2006Assignee: Dow AgroSciences LLCInventors: Jerald S. Feitelson, H. Ernest Schnepf, Kenneth E. Narva, Brian A. Stockhoff, James Schmeits, David Loewer, Charles Joseph Dullum, Judy Muller-Cohn, Lisa Stamp, George Morrill, Stacey Finstad-Lee
-
Patent number: 7033788Abstract: The present invention relates to Saxatilin, a protein derived from the venom of a Korean snake, Agkistrodon saxatilis emelianov, a process for preparing Saxatilin, and pharmaceutical application of the same as anti-platelet aggregation agent and anti-tumor agent. The present inventors purified Saxatilin from the venom of Agkistrodon saxatilis emelianov, cloned its cDNA, and prepared recombinant Saxatilin by culturing a microorganism transformed with an expression vector containing the cDNA. Saxatilin effectively suppresses the platelet aggregation and angiogenesis of tumor cells, which makes possible its practical application as an active ingredient of anti-platelet agent and anti-tumor agent.Type: GrantFiled: March 26, 2002Date of Patent: April 25, 2006Inventors: Kwang-Hoe Chung, Doo-sik Kim, Sung-Yu Hong, You-Seok Koh, Young-Doug Sohn, Weon-Kyoo You, Yang-Soo Jang, Chin-Kyu Huh
-
Patent number: 7022490Abstract: The present invention provides assays for determining transcription-modulating substances. The transcription-modulating activity of test compounds is assessed on the basis of their ability to suppress or enhance complex formation between Myc and a novel zinc finger binding protein, Miz-1, or derivatives thereof.Type: GrantFiled: July 24, 2000Date of Patent: April 4, 2006Assignee: Prolifix LimitedInventors: Karen Peukert, Frank Haenel, Martin Eilers
-
Patent number: 7014993Abstract: The present invention provides a DNA encoding a Tumor Antigen Derived Gene TADG-14 protein selected from the group consisting of: (a) isolated DNA which encodes a TADG-14 protein; (b) isolated DNA which hybridizes to isolated DNA of (a) above and which encodes a TADG-14 protein; and (c) isolated DNA differing from the isolated DNAs of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a TADG-14 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell.Type: GrantFiled: August 21, 1997Date of Patent: March 21, 2006Assignee: The Board of Trustees of the University of ArkansasInventors: Timothy J. O'Brien, Lowell J. Underwood
-
Patent number: 7011946Abstract: The present invention provides novel in vivo assay systems and methods of using these assays systems to identify compounds that affect microbial cell division. The present invention further provides pharmaceutical compositions that have anti-microbial activity and methods of treating microbial infections.Type: GrantFiled: June 26, 2002Date of Patent: March 14, 2006Assignees: Trustees of Tufts College, President and Fellows of Harvard CollegeInventors: Debabrata RayChaudhuri, Marc Kirschner
-
Patent number: 6958323Abstract: The present invention relates to the use of ?-conotoxin peptides having the general formula Xaa1-Xaa2-Cys-Cys-Xaa3-Xaa4-Pro-Xaa5-Cys-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Cys (SEQ ID NO:1) for treating disorders regulated at neuronal nicotinic acetylcholine receptors. Such disorders include, but are not limited to, cardiovascular disorders, gastric motility disorders, urinary incontinence, nicotine addiction, mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and small cell lung carcinoma, as well as the localization of small cell lung carcinoma. In this formula, Xaa1 is des-Xaa1, Tyr, mono-iodo-Tyr or di-iodo-Tyr, Xaa2 is any amino acid, Xaa3 is any amino acid, Xaa4 is any amino acid, Xaa5 is any amino acid; Xaa6 is any amino acid, Xaa7 is any amino acid, Xaa8 is any amino acid, Xaa9 is des-Xaa9 or any amino acid, Xaa10 is des-Xaa10 or any amino acid, Xaa11 is des-Xaa11 or any amino acid and Xaa2 is des-Xaa12 or any amino acid.Type: GrantFiled: July 3, 2001Date of Patent: October 25, 2005Assignees: University of Utah Research Fnd., Cognetix, Inc.Inventors: Baldomero M. Olivera, J. Michael McIntosh, Doju Yoshikami, G. Edward Cartier, Siqin Luo
-
Patent number: 6953835Abstract: A method for producing genetically transformed plants exhibiting toxicity to Coleopteran insects is disclosed. In another aspect, the present invention embraces chimeric plant genes, genetically transformed cells and differentiated plants which exhibit toxicity to Coleopteran insects. In yet another aspect, the present invention embraces bacterial cells and plant transformation vectors comprising a chimeric plant gene encoding a Coleopteran toxin protein of Bacillus thuringiensis.Type: GrantFiled: August 31, 2001Date of Patent: October 11, 2005Assignee: Monsanto Technology LLCInventors: David A. Fischhoff, Roy L. Fuchs, Paul B. Lavrik, Sylvia A. McPherson, Frederick J. Perlak
-
Patent number: RE39240Abstract: Substantially pure conotoxins are provided which inhibit synaptic transmissions at the neuromuscular junctions and which are useful both in vivo and in assays because they specifically target particular receptors, such as the acetyl-choline receptor, and ion channels. The peptides are of such length that they can be made by chemical synthesis. They also may be made using recombinant DNA techniques, and the DNA encoding such conotoxins having pesticidal properties can be incorporated as plant defense genes into plant species of interest.Type: GrantFiled: December 22, 1999Date of Patent: August 15, 2006Assignees: University of Utah Research Foundation, The Salk Institute for Biological StudiesInventors: Baldomero M. Olivera, Jean E. F. Rivier, Lourdes J. Cruz, Fe Abogadie, Chris E. Hopkins, John Dykert, Josep L. Torres